HIPAA vs SOC 2 vs HITRUST for Digital Health

After the first payer contract, digital health leaders face the same three-way question: HIPAA is the law, SOC 2 is in the contract, and HITRUST is what the payer's risk team "strongly prefers." Comparing them as checkboxes misses what actually matters operationally — they're three different verification models sampling largely the same underlying evidence. Choose your evidence strategy well and the three become one program with three outputs; choose poorly and you'll run three parallel audits forever.

This comparison looks at the three through the lens that matters post-payer-deal: what each one verifies, who accepts it, what evidence it samples, and how to sequence them without tripling the workload.

Key Takeaways: HIPAA vs SOC 2 vs HITRUST

• HIPAA is a legal obligation verified retrospectively (investigations, audits); SOC 2 is an auditor's opinion over an observation period; HITRUST is a certifying assessment with maturity scoring.
• Market acceptance differs: SOC 2 satisfies most enterprise buyers; HITRUST is the payer/health-system gold standard; HIPAA compliance is assumed, not celebrated.
• All three sample the same delivery evidence — change control, testing, remediation — which is where a shared evidence base pays off.
• Sequence for most digital health startups: HIPAA program from day one, SOC 2 Type II for sales, HITRUST when payers demand it.
• The losing strategy is per-framework evidence collection; the winning one is release-linked capture serving all three.

What Each One Actually Is

HIPAA is regulation: Privacy, Security, and Breach Notification Rules binding covered entities and business associates. There is no certificate — verification happens retrospectively, through OCR investigations after incidents and through your customers' audits. Its evidence demand is therefore standing readiness: produce the record when asked, often about a window months past. SOC 2 is an attestation: a CPA firm's opinion that your controls met the Trust Services Criteria over an observation period (Type II). It exists for buyers — the report answers enterprise procurement. HITRUST is certification: an assessor-validated evaluation against the CSF with maturity scoring, heavily weighted toward demonstrated implementation. Payers and health systems treat it as the strongest signal because it's the most prescriptive and the hardest to talk your way through.

Where They Overlap — and Where They Don't

The organizational layers differ meaningfully: HIPAA demands privacy-specific artifacts (BAAs, minimum-necessary analyses, breach procedures); SOC 2 flexes to your control descriptions; HITRUST prescribes controls with required maturity. But at the delivery layer they converge almost completely: all three sample change control on regulated systems, testing evidence, access governance, and vulnerability remediation. A change to an ePHI-handling service needs the same connected record — structured change, policy-recorded approval, test execution, deployment, SLA-tracked remediation — whether the sampler is an OCR investigator, a SOC 2 auditor, or a HITRUST assessor. Build that chain once and the frameworks differ mainly in packaging.

Sequencing for a Digital Health Company

Day one: HIPAA program. It's the law and the floor — policies, BAAs, training, and critically, release audit trails on ePHI systems, because HIPAA's verification is retrospective and unscheduled. First enterprise sales cycle: SOC 2 Type II. It unblocks procurement broadly and its observation period rewards early evidence automation. First payer insisting: HITRUST (start with e1/i1 tiers if acceptable to the payer; r2 when required). Its implementation-scored model is where teams with generated evidence dramatically outperform teams with collected evidence. At each step the marginal cost drops if the delivery layer is shared: compliance objectives map one evidence stream to all three frameworks, and the Release Compliance Dossier becomes the artifact every audience samples.

The Strategic Mistake to Avoid

The expensive path is treating each framework as its own project with its own spreadsheet: HIPAA evidence assembled during an incident, SOC 2 evidence reconstructed each audit season, HITRUST evidence screenshot-farmed before assessment. Each collection pass costs engineer-weeks and produces copies with a copy's integrity. The alternative is architectural: capture delivery evidence at the source, continuously, scoped by system — then every framework's sample, every payer questionnaire, and every OCR window is served from the same living record.

In Conclusion

HIPAA is the law, SOC 2 is the sales unlock, HITRUST is the payer standard — three verification models, one underlying evidence chain. Digital health teams that centralize release-linked evidence run one program with three outputs; teams that don't run three programs that each rediscover the same gaps. The comparison ends where the architecture begins.

FAQs about HIPAA vs SOC 2 vs HITRUST

What's the fundamental difference between the three?

Verification model: HIPAA is law verified retrospectively through investigations and customer audits; SOC 2 is a CPA firm's attestation over an observation period; HITRUST is a certifying assessment with maturity scoring weighted toward demonstrated implementation.

Which one do payers and health systems actually want?

HITRUST is the payer and health-system gold standard because it's prescriptive and hard to talk through; SOC 2 satisfies most enterprise buyers; HIPAA compliance is assumed as the floor rather than credited as a differentiator.

How should a digital health startup sequence them?

HIPAA program from day one (it's the law and verification is unscheduled), SOC 2 Type II when enterprise sales demand it, and HITRUST when a payer insists — starting with e1/i1 tiers where acceptable.

How much of the evidence is shared across all three?

At the delivery layer, nearly all of it: change control on regulated systems, testing evidence, access governance, and remediation trails. One release-linked chain serves all three samplers; only the policy-layer packaging differs.